Massachusetts-based Mevion Medical secured $55 million in funding in support of accelerated deployment of the company’s single-room-proton therapy systems, a smaller, cheaper radiation therapy system for targeting cancerous tumors.
Mevion reported that it raised the funds from existing equity investors Caxton Heath Life Sciences, ProQuest Investments, Venrock, and CHL Medical Partners, as well as through debt financing provided by Life Sciences Alternative Funding.